Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Downgrades Aptinyx to Neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aptinyx (NASDAQ:APTX) from Buy to Neutral.

byBenzinga Newsdesk

March 7, 2023

1 minute read

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aptinyx (NASDAQ:APTX) from Buy to Neutral.

Call Of Duty: Microsoft Prepares To Fight FTC Lawsuit Over Activision Deal

By AJ Fabino

Today, 10:08 AM

Microsoft Corp (NASDAQ: MSFT) indicated that it plans to challenge the Federal Trade Commissions’s lawsuit to block its $68.7 billion deal — $95 per share — to acquire video-game developer Activison Blizzard Inc (NASDAQ:

ATVI

Raymond James Initiates Coverage On Waldencast with Outperform Rating, Announces Price Target of $11

By Benzinga Newsdesk

Today, 10:08 AM

Raymond James analyst Olivia Tong initiates coverage on Waldencast (NASDAQ:WALD) with a Outperform rating and announces Price Target of $11.

WALD

News

Exxon Mobil Spokesperson Says Gradually Shuts 235,000 BPD Fos-sur-Mer Oil Refinery In France On Strike Action

By Benzinga Newsdesk

Today, 10:08 AM

- Reuters

EWQ

Qualigen Therapeutics Announces $8.82M Offering

By Benzinga Newsdesk

Today, 10:08 AM

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship

QLGN

HC Wainwright & Co. Downgrades Aptinyx to Neutral

Related Posts

Call Of Duty: Microsoft Prepares To Fight FTC Lawsuit Over Activision Deal

Raymond James Initiates Coverage On Waldencast with Outperform Rating, Announces Price Target of $11

Exxon Mobil Spokesperson Says Gradually Shuts 235,000 BPD Fos-sur-Mer Oil Refinery In France On Strike Action

Qualigen Therapeutics Announces $8.82M Offering